AbstractBackgroundSemaglutide is a GLP-1 receptor agonist that provides a reduction in glycated hemoglobin and weight. The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes and adverse effects (AE).MethodsThe data bases Pubmed, Lilacs, Scielo, Scopus, Web of Science and Cochrane Library were surveyed.ResultsInitially, 3333 articles were found, of which 19 articles were included.

摘要背景Semaglutide是一种GLP-1受体激动剂，可降低糖化血红蛋白和体重。目的是评估在超重或肥胖患者中使用semaglutide是否会降低心血管结局和不良反应（AE）。方法对Pubmed、Lilacs、Scielo、Scopus、Web of Science和Cochrane图书馆的数据库进行调查。结果初步发现3333篇文章，其中19篇被纳入。

An additional search included 19 studies, totaling 38 articles. Relative risk (RR) values were significant for hospitalization due to heart failure (HF) 0.24 95% CI 0.12–0.57 (n = 2; 1045 participants; I² = 0.18), death due to cardiovascular causes 0.83 95% CI 0.71–0.98 (n = 3; 24 084 participants; I² = 0.21), death from any cause 0.79 95% CI 0.70–0.89 (n = 3; 24 084 participants; I² = 0.07), coronary revascularization 0.76 95% CI 0.69–0.85 (n = 2;20 951 participants; I² = 0.41), and non-fatal myocardial infarction 0.76 95%CI 0.66–0.88 (n = 3; 24 084 participants; I² = 0.21), with a difference between the subgroups (p = 0.05), favoring the subcutaneous administration route.

另外的搜索包括19项研究，共38篇文章。心力衰竭（HF）住院的相对危险度（RR）值为0.24 95%CI 0.12-0.57（n＝2）；1045名参与者；I²=0.18），心血管原因死亡0.83 95%CI 0.71-0.98（n=3）；24 084名参与者；I²=0.21），任何原因死亡0.79 95%可信区间0.70-0.89（n=3）；24 084名参与者；I²=0.07），冠状动脉血运重建0.76 95%CI 0.69-0.85（n=2）；20 951名参与者；I²=0.41），非致命性心肌梗死0.76 95%CI 0.66-0.88（n=3）；24 084名参与者；I²=0.21），亚组之间存在差异（p=0.05），有利于皮下给药途径。

The RR of stroke was 0.65 95% CI 0.44–0.97 for patients with diabetes (n = 2; 6480 participants; I² = 0.66). There was no difference between the frequency of constipation and routes of administration, as well as between doses of oral semaglutide. The RR of adverse effects was only not significant for discontinuation of treatment for oral semaglutide.ConclusionThe use of semaglutide reduced 76% in hospitalization due to HF, 17% deaths due to cardiovascular causes, 21% deaths due to any cause, 24% non-fatal myocardial infarction, 24% coronary revascularization and 35% stroke (in patients with diabetes).

糖尿病患者的卒中RR为0.65 95%CI 0.44-0.97（n＝2）；6480名参与者；I²=0.66）。便秘的频率和给药途径以及口服semaglutide的剂量之间没有差异。不良反应的RR仅在停止口服semaglutide治疗时不显着。结论使用semaglutide可减少HF住院率76%，心血管原因死亡17%，任何原因死亡21%，非致命性心肌梗死24%，冠状动脉血运重建24%，中风35%（糖尿病患者）。

The use of semaglutide was associated with .

semaglutide的使用与。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Subscribe to this journalReceive 12 print issues and online access251,40 € per yearonly 20,95 € per issueLearn moreBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout

订阅本期刊每年可收到12期印刷版和在线访问251,40欧元每期仅20,95欧元了解更多在SpringerLink上购买本文立即访问全文PDFBuy NOW价格可能需要缴纳结帐时计算的当地税费

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

Fig. 1Fig. 2Fig. 3Fig. 4Fig. 5

图1图。图2。3图。4图。5

ReferencesLobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. World Obesity. Acessed April 5, 2024. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes.

参考文献Lobstein T，Jackson-Leach R，Powis J，Brinsden H，Gray M.世界肥胖图谱2023。世界肥胖。2024年4月5日通过。https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.LincoffAM，Brown-Frandsen K，Colhoun HM，Deanfield J，Emerson SS，Esbjerg S等。Semaglutide和无糖尿病肥胖的心血管结局。

N Engl J Med. 2023;389:2221–2232. https://doi.org/10.1056/nejmoa2307563.Article .

《新英格兰医学杂志》2023年；389:2221–2232.https://doi.org/10.1056/nejmoa2307563.Article.

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20:463–474. https://doi.org/10.1038/s41569-023-00849-3.Article

Ussher JR，Drucker DJ。胰高血糖素样肽1受体激动剂：心血管益处和作用机制。Nat Rev Cardiol公司。2023年；20： 463-474年。https://doi.org/10.1038/s41569-023-00849-3.Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Brunton LL, Chabner BA, Knollmann BC. As Bases Farmacológicas Da Terapêutica de Goodman & Gilman. 12th ed. AMGH Editora Ltda; 2012.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

布伦顿LL，夏布纳BA，诺尔曼BC。作为古德曼和吉尔曼农场的基地。第12版AMGH Editora Ltda；2012年。Page MJ，McKenzie JE，Bossuyt PM，Boutron I，Hoffmann TC，Mullow CD等。PRISMA 2020声明：报告系统评价的更新指南。

BMJ. 2021;372. https://doi.org/10.1136/bmj.n71.Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https://doi.org/10.1136/bmj.l4898.Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial.

英国医学杂志。2021年；372https://doi.org/10.1136/bmj.n71.SterneJAC，SavovićJ，Page MJ，Elbers RG，Blencowe NS，Boutron I等。RoB 2：评估随机试验偏倚风险的修订工具。英国医学杂志。；366https://doi.org/10.1136/bmj.l4898.BalduzziS，Rücker G，Schwarzer G.如何使用R进行荟萃分析：实用教程。

Evid Based Ment Health. 2019;22:153–160. https://doi.org/10.1136/ebmental-2019-300117.Article .

基于Evid的健康。；22:153-160。https://doi.org/10.1136/ebmental-2019-300117.Article。

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl J Med. 2016;375:1834–1844. https://doi.org/10.1056/nejmoa1607141.Article

Marso SP，Bain SC，Consoli A，Eliaschewitz FG，Jódar E，Leiter LA等。Semaglutide与2型糖尿病患者的心血管结局。N、 英国医学杂志2016；375:1834年至1844年。https://doi.org/10.1056/nejmoa1607141.Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394–1407.Article

Kosiborod MN，Petrie MC，Borlaug BA，Butler J，Rasmussen S，Davies M等。Semaglutide治疗肥胖相关性心力衰竭和2型糖尿病患者。英格兰医学杂志2024；390:1394–1407.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Dwibedi C, Ekström O, Brandt J, Adiels M, Franzén S, Abrahamsson B, et al. Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nat Metab. 2024;6:50–60. https://doi.org/10.1038/s42255-023-00943-3.Article

Dwibedi C，Ekström O，Brandt J，Adiels m，Franzén S，Abrahamsson B等。semaglutide和dapagliflozin在不同病理生理学的2型糖尿病患者中的随机开放标签试验。自然代谢。2024年；6： 50-60岁。https://doi.org/10.1038/s42255-023-00943-3.Article

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387:2245–2257. https://doi.org/10.1056/nejmoa2208601.Article

Weghuber D，Barrett T，Barrientos-Pérez M，Gies I，Hesse D，Jeppesen OK等。肥胖青少年每周一次服用semaglutide。英格兰医学杂志2022；387:2245年至2257年。https://doi.org/10.1056/nejmoa2208601.Article

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515–527.

Mosenzon O，Blicher TM，Rosenlund S，Eriksson JW，Heller S，Hels OH等。口服semaglutide对2型糖尿病和中度肾功能不全患者的疗效和安全性（PIONEER 5）：安慰剂对照，随机，3a期试验。柳叶刀糖尿病内分泌。；7： 515年至527年。

https://doi.org/10.1016/S2213-8587(19)30192-5.Article .

https://doi.org/10.1016/S2213-8587（19） 30192-5.第一条。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Sivalingam S, Wasehuus VS, Curovic VR, Blond MB, Hansen TW, Persson F, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26:54–64. https://doi.org/10.1111/dom.15287.Article .

Sivalingam S，Wasehuus VS，Curovic VR，Blond MB，Hansen TW，Persson F等。2型糖尿病患者在依帕列净基础上添加semaglutide降低白蛋白尿的作用：一项随机和安慰剂对照研究。糖尿病Obes代谢。2024年；26:54-64。https://doi.org/10.1111/dom.15287.Article。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Villegas ECM, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724–1732. https://doi.org/10.2337/dc19-0749.Article .

Aroda VR，Rosenstock J，Terauchi Y，Altuntas Y，Lalic NM，Villegas ECM等。先锋1：口服semaglutide单药治疗与安慰剂治疗2型糖尿病患者的疗效和安全性的随机临床试验。糖尿病护理。；42:1724年至1732年。https://doi.org/10.2337/dc19-0749.Article。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl J Med. 2019;381:841–851. https://doi.org/10.1056/nejmoa1901118.Article

Husain M，Birkenfeld AL，Donsmark M，Dungan K，Eliaschewitz FG，Franco DR等。口服semaglutide与2型糖尿病患者的心血管结局。N、 英国医学杂志2019；381:841-851。https://doi.org/10.1056/nejmoa1901118.Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese Patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol.

Yamada Y，Katagiri H，Hamamoto Y，Deenadayalan S，Navarria A，Nishijima K等。日本2型糖尿病患者口服semaglutide单药治疗的剂量反应，疗效和安全性（PIONEER 9）：52周，2/3a期，随机对照试验。柳叶刀糖尿病内分泌。

2020;8:377–391. https://doi.org/10.1016/S2213-8587(20)30075-9.Article .

2020;8:377-391.https://doi.org/10.1016/S2213-8587（20） 30075-9.文章。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs. daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. JAMA. 2022;327:138–150. https://doi.org/10.1001/jama.2021.23619.Article .

Rubino DM，Greenway FL，Khalid U，O'Neil PM，Rosenstock J，Sørrig R等。每周皮下注射semaglutide与每日利拉鲁肽对超重或肥胖无糖尿病成年人体重的影响：第8步随机临床试验。杰玛。2022年；327:138-150。https://doi.org/10.1001/jama.2021.23619.Article。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and Efficacy of Oral Semaglutide versus Dulaglutide in Japanese Patients with Type 2 Diabetes (PIONEER 10): An Open-Label, Randomised, Active-Controlled, Phase 3a Trial. 8. Lancet Diabetes Endocrinol. 2020.

Yabe D，Nakamura J，Kaneto H，Deenadayalan S，Navarria A，Gislum M等。口服Semaglutide与杜拉鲁肽在日本2型糖尿病患者中的安全性和有效性（PIONEER 10）：一项开放标签，随机，主动对照，3a期试验。柳叶刀糖尿病内分泌。2020

8:392-406. https://doi.org/10.1016/S2213-8587(20)30074-7.Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705–719.

8： 392-406年。https://doi.org/10.1016/S2213-8587（20） 。柳叶刀。2023年；402:705-719。

https://doi.org/10.1016/S0140-6736(23)01185-6.Article .

https://doi.org/10.1016/S0140-6736（23）01185-6.第九条。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA J Am Med Assoc. 2021;325:1414–1425. https://doi.org/10.1001/jama.2021.3224.Article .

Rubino D，Abrahamsson N，Davies M，Hesse D，Greenway FL，Jensen C等。每周持续皮下注射semaglutide与安慰剂对超重或肥胖成年人减肥维持的影响：第4步随机临床试验。JAMA J Am Med Assoc.2021；325:1414年至1425年。https://doi.org/10.1001/jama.2021.3224.Article。

CAS

中科院

Google Scholar

谷歌学者

Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402:693–704. https://doi.org/10.1016/S0140-6736(23)01127-3.Article .

Aroda VR，Aberle J，Bardtrum L，Christiansen E，Knop FK，Gabery S等。每日一次口服semaglutide 25 mg和50 mg与成人2型糖尿病患者14 mg相比的疗效和安全性（PIONEER PLUS）：一项多中心，随机，3b期试验。柳叶刀。2023年；402:693-704。https://doi.org/10.1016/S0140-6736（23）01127-3。条款。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/nejmoa2032183.Article

Wilding JPH，Batterham RL，Calanna S，Davies M，Van Gaal LF，Lingvay I等。超重或肥胖成年人每周一次服用semaglutide。英格兰医学杂志2021；384:989年至1002年。https://doi.org/10.1056/nejmoa2032183.Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–1084. https://doi.org/10.1056/nejmoa2306963.Article

Kosiborod MN，Abildstrøm SZ，Borlaug BA，Butler J，Rasmussen S，Davies m等。Semaglutide治疗射血分数和肥胖保留的心力衰竭患者。英格兰医学杂志2023；389:1069年至1084年。https://doi.org/10.1056/nejmoa2306963.Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–113. https://doi.org/10.1016/S2213-8587(17)30412-6.Article .

Bethel MA，Patel RA，Merrill P，Lokhnygina Y，Buse JB，Mentz RJ等。2型糖尿病患者胰高血糖素样肽-1受体激动剂的心血管结局：荟萃分析。柳叶刀糖尿病内分泌。；6： 105–113。https://doi.org/10.1016/S2213-8587（17） 30412-6条。

PubMed

PubMed

Google Scholar

谷歌学者

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776–785.

Kristensen SL，Rørth R，Jhund PS，Docherty KF，Sattar N，Preiss D等。2型糖尿病患者GLP-1受体激动剂的心血管，死亡率和肾脏结局：心血管结局试验的系统评价和荟萃分析。柳叶刀糖尿病内分泌。；7： 776-785。

https://doi.org/10.1016/S2213-8587(19)30249-9.Article .

https://doi.org/10.1016/S2213-8587（19） 30249-9.第九条。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130. https://doi.org/10.1016/S0140-6736(19)31149-3.Article

Gerstein HC，Colhoun HM，Dagenais GR，Diaz R，Lakshmanan M，Pais P等。杜拉鲁肽与2型糖尿病心血管结局（REWIND）：一项双盲，随机安慰剂对照试验。柳叶刀。；394:121-130。https://doi.org/10.1016/S0140-6736（19） 31149-3.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. https://doi.org/10.1056/nejmoa1603827.Article

Marso SP，Daniels GH，Brown-Frandsen K，Kristensen P，Mann JFE，Nauck MA等。利拉鲁肽与2型糖尿病的心血管结局。英格兰医学杂志2016；375:311–322。https://doi.org/10.1056/nejmoa1603827.Article

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Nauck MA, Meier JJ. Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211–R234. https://doi.org/10.1530/EJE-19-0566.Article

Nauck MA，Meier JJ。所有GLP-1激动剂在治疗2型糖尿病方面是否相同？Eur J内分泌。；181:R211–R234。https://doi.org/10.1530/EJE-19-0566.Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Tan HCQ, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37:65–72. https://doi.org/10.15605/jafes.037.02.14.Article

Tan HCQ，Dampil OA，Marquez MM。semaglutide对无糖尿病肥胖患者减肥的有效性和安全性：系统评价和荟萃分析。J东盟联邦经济委员会，2022年；37:65-72。https://doi.org/10.15605/jafes.037.02.14.Article

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12. https://doi.org/10.3389/fendo.2021.645563.Download referencesAcknowledgementsNo source of support was used to carry out this work.Author informationAuthors and AffiliationsState University of Ponta Grossa, Department of Medicine, Paraná, BrazilAndré Saad Cleto, João Matheus Schirlo, Mayara Beltrame, Victor Hugo Oliveira Gomes, Isabela Hellmann Acras, Guinter Sponholz Neiverth, Breno Bach Silva, Beatriz Moreira Salles Juliatto, Janete Machozeki & Camila Marinelli MartinsAuthorsAndré Saad CletoView author publicationsYou can also search for this author in.

Smits MM，Van Raalte DH。Semaglutide的安全性。前内分泌。2021年；12https://doi.org/10.3389/fendo.2021.645563.Download参考文献致谢没有支持这项工作的来源。作者信息作者和附属机构蓬塔格罗萨州立大学医学系，巴拉那州，巴西安德烈萨阿德·克莱托，若昂·马修斯·斯基洛，玛亚拉·贝尔特拉姆，维克多·雨果·奥利维拉·戈麦斯，伊莎贝拉·赫尔曼·阿克拉斯，吉尼特·斯波霍尔茨·内维尔，布伦诺·巴赫·席尔瓦，比阿特丽兹·莫雷拉·萨利斯·朱利亚托，珍妮特·马切基和卡米拉·马里内利·马丁索·桑德雷萨阿德·克莱托查看作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarJoão Matheus SchirloView author publicationsYou can also search for this author in

PubMed Google ScholarJoão Matheus SchirloView作者出版物您也可以在

PubMed Google ScholarMayara BeltrameView author publicationsYou can also search for this author in

PubMed Google ScholarMayara BeltrameView作者出版物您也可以在

PubMed Google ScholarVictor Hugo Oliveira GomesView author publicationsYou can also search for this author in

PubMed谷歌学者维克托·雨果·奥利维拉·戈梅斯view作者出版物您也可以在

PubMed Google ScholarIsabela Hellmann AcrasView author publicationsYou can also search for this author in

PubMed Google ScholarIsabela Hellmann AcrasView作者出版物您也可以在

PubMed Google ScholarGuinter Sponholz NeiverthView author publicationsYou can also search for this author in

PubMed Google ScholarGuinter Sponholz NeiverthView作者出版物您也可以在

PubMed Google ScholarBreno Bach SilvaView author publicationsYou can also search for this author in

PubMed Google ScholarBeatriz Moreira Salles JuliattoView author publicationsYou can also search for this author in

PubMed Google ScholarBeatriz Moreira Salles JuliattoView作者出版物您也可以在

PubMed Google ScholarJanete MachozekiView author publicationsYou can also search for this author in

PubMed谷歌学者Janete MachozekiView作者出版物您也可以在

PubMed Google ScholarCamila Marinelli MartinsView author publicationsYou can also search for this author in

PubMed Google ScholarCamila Marinelli MartinsView作者出版物您也可以在

PubMed Google ScholarContributionsASC, JMS, MB, VHOG, IHA, GSN, BMSJ and BBS were responsible for reading titles, abstracts and full articles, as well as for data extraction and writing the article. Furthermore, ASC was responsible for carrying out the meta-analyses with the author CMM.

。此外，ASC负责与作者CMM进行荟萃分析。

CMM and JM supervised the other authors and assisted in writing the article and correcting the manuscript after peer review.Corresponding authorCorrespondence to.

CMM和JM监督了其他作者，并在同行评审后协助撰写文章和更正稿件。对应作者对应。

André Saad Cleto.Ethics declarations

安德烈·萨阿德·克莱托。道德宣言

Competing interests

相互竞争的利益

The authors declare no competing interests.

作者声明没有利益冲突。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationSupplemental MaterialRights and permissionsSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Reprints and permissionsAbout this articleCite this articleCleto, A.S., Schirlo, J.M., Beltrame, M.

Additional informationPublisher的注释Springer Nature在已发布地图和机构隶属关系中的管辖权主张方面保持中立。补充信息补充材料权利和许可Pringer Nature或其许可方（例如协会或其他合作伙伴）根据与作者或其他权利持有人的出版协议对本文拥有专有权；本文接受稿件版本的作者自行存档仅受此类出版协议和适用法律的条款管辖。转载和许可本文引用本文Cleto，A.S.，Schirlo，J.M.，Beltrame，M。

et al. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis..

Semaglutide对超重或肥胖患者安全性和心血管结局的影响：系统评价和荟萃分析。。

Int J Obes (2024). https://doi.org/10.1038/s41366-024-01646-9Download citationReceived: 09 June 2024Revised: 24 September 2024Accepted: 27 September 2024Published: 12 October 2024DOI: https://doi.org/10.1038/s41366-024-01646-9Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Int J Obes（2024年）。https://doi.org/10.1038/s41366-024-01646-9Download引文收到日期：2024年6月9日修订日期：2024年9月24日接受日期：2024年9月27日发布日期：2024年10月12日OI：https://doi.org/10.1038/s41366-024-01646-9Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供